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Background: Rheumatoid arthritis (RA) is an 
autoimmune disease which has recently been 
recognized to manifest as not only intraarticular but also 
extraarticular symptoms. Cardiovascular events, 
presented either subclinically or clinically, were 
discovered more in AR patients. Atherogenic 
inflammatory mediator in AR including interleukin-6 (IL-6) 
was thought to be one of nontraditional cardiovascular 
risk factor contributing to increase the endothelial 
dysfunction biomarker such as E-Selectin. This study 
was purposed to determine the correlation between 
inflammatory mediator and endothelial dysfunction event, 
especially between IL-6 and E-Selectin, in RA patient 
without traditional cardiovascular risk factor. Method: A 
cross-sectional study was performed  
to 40 RA patients of Rheumatology Clinic of Cipto 
Mangunkusumo National General Hospital, Indonesia from 
September to November 2017. Measurement of the level 
of IL-6 and E-Selectin were performed using enzyme-
linked immunosorbent assay (ELISA). Bivariate correlation 
analysis was performed to determine the correlation 
between those two biomarkers. 
 
Result: The mean age of this study subjects was 
44.9 (13.1) years and median of disease duration 
was 36 months. This study showed weak 
correlation between IL-6 and E-Selectin level, but 
not statistically significant.232, p=0.149).  
Conclusion: There is weak correlation between 
IL-6 and sE-Selectin in rheumatoid arthritis patient 
without traditional risk factor cardiovascular  
Keywords: traditional risk factor 
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Rheumatoid arthritis (RA) is an autoimmune dis-
ease which is characterized by chronic inflamma-
tion and causes progressive disability, early mor-
tality, and socioeconomic burden culminating in 
clinical deterioration and worsening prognosis. 
This disease has a prevalence of 0.5-1%, can occur 
in every ethnic, and occasionally attacks young-
aged women. The major manifestation of RA is 
inflammatory arthritis affecting diarthrodial joints, 
particularly small joints, with a tendency presenta- 
 
 
tion of symmetric polyarthritis. Most of RA cases 
have chronic progressive nature. Untreated or in-
adequately treated disease will cause articular car-
tilage and juxtaarticular bone destruction, which 
results in permanent joint damage. In consequence, 
comprehensive management is required to manage 
articular symptoms as well as to prevent the poten-tial 
systemic complications in RA.1  
Rheumatoid arthritis may present as intraar-
ticular manifestations of joints damage; however, it 
may be accompanied with extraarticular compli-
cations, the condition of which becomes a major 
problem. One possible systemic extraarticular com-
plication in RA is cardiovascular disease. In the last 
half century, increasing cardiovascular events have 
been reported on inflammatory rheumatic patients, 
particularly in RA. RA patients have twice the mor-
tality rate compared to the general populations. As 
much as 30-50% of the mortality is related to 
cardiovascular events, the most common of which 
is ischemic heart disease and cerebrovascular dis-
ease.2  
Cardiovascular events in RA occur due to tra-
ditional and nontraditional risk factors related to the 
chronic inflammation. Chronic inflammation 
results in endothelial dysfunction, which eventu-
ally triggers an early atherosclerosis. However, to 
date, there are still no theories which are capable to 
explain the exact pathogenesis of endothelial dys-
function in RA.  
Some cytokines are well-known for contribut-ing 
in RA pathogenesis, including tumor necrosis factor-
alpha (TNF-α), interleukin-6 (IL-6), and interleukin-
17 (IL-17). Among those proinflamma-tory cytokines, 
IL-6 has been widely studied as one of the most 
important cytokine in the pathogenesis of RA. This 
cytokine has pleiotropic effect in influ-encing 
systemic inflammation via the hematopoi-etic and 
immune system as well as in inducing the production 
of acute phase reactant - such as C-re-active protein 
(CRP) - from hepatocyte, influencing the maturity of 
B cells and inducing the production of autoantibodies, 
having a role in endothel activa-tion, and stimulating 
osteoclast maturation result-ing in bone erosion. In the 
metabolism of lipid, IL-6 has been recognized to 
stimulate the synthesis of hepatic fatty acid and the 
lypolisis of adipose tissue 
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as well as to promote the synthesis of and reduce the secretion of 
cholesterol.3 Those conditions were thought to contribute in the 
occurrence of atherosclerosis in AR. Increased IL-6 and CRP 
levels may be attributed to the increased risk of cardio-vascular 
events in both male4 and female,5 as well as to the increase in 
mortality due to acute coronary syndrome. Those risk is not 
dependent on other traditional risk factors, includ-ing 
dyslipidemia. The role of IL-6 in endothelial dysfunction has 
been studied considerably in many populations. Esteve, et al. had 
reported that in healthy male, IL-6 had a correlation with 
endothelial dysfunction measured by endothelial-inde-pendent 
vasodilatation test of brachial artery.6  
The early sign of atherosclerosis is endothelial dysfunc-
tion. The process of endothelial dysfunction involves various 
factors, including genetics, traditional cardiovascular risk fac-
tors, and systemic inflammation. Traditional cardiovascular 
risk factors, including smoking, hypertension, dyslipidemia, 
obesity, and diabetes, play a greatly important role in the de-
velopment of endothelial dysfunction. Currently, many bio-
markers of endothelial dysfunction have been developed.7 The 
most commonly observed adhesion molecule in various stud-
ies are soluble E-selectin (sE-selectin), intercellular adhesion 
molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 
(VCAM-1).  
Many previous studies have proved the correlation be-
tween those adhesion molecules and the development of en-
dothelial dysfunction, including in RA. E-selectin, being the 
most specific adhesion molecule synthesized by endothelial 
cells, has also been proven to be correlated with endothelial 
dysfunction. The expression of E-selectin begins with the ac-
tivation and production of IL-6, TNF-α, and CRP.8,9 Hwang, 
et al. described that sE-selectin can be used as a biomarker of 
atherosclerosis and the development of coronary heart dis-
ease.10  
A few studies have described the correlation between IL-6 
and E-selectin, including Dessein, et al. in 2006 (r= 0.43, 
p<0,0005)11 and in 2013 (r=0,25, p<0,0001).12 Nevertheless, those 
studies include subjects with traditional cardiovascular risk 
factors, such as hypertension, diabetes, smoking, and dys-
lipidemia. To date, no studies have measured the correlation 
between those variables independently. This study was spe-
cifically aimed to determine the correlation between IL-6 and E-
selectin as the biomarker of endothelial dysfunction in RA 
patients without any traditional cardiovascular risk factors. 
 
Method 
This cross-sectional study was performed in Cipto 
Mangunkusumo National General Hospital - a national 
referral hospital in Indonesia – after receiving the approval 
from FKUI Research Ethical Committee. Some subjects in 
this study were retrospectively obtained from a previous study 
“Role of Hydroxychloroquine to Improve Endothelial 
Dysfunction in Patients with Rheumatoid Arthritis,” the 
recruitment period of which was in August 2016, whereas the 
other subjects were recruited consecutively from 
Rheumatology Polyclinic of Cipto Mangunkusumo National 
General hospital, the recruitment period of which was in 
October to December 2017. 
 
 
Subjects included in this study were those diagnosed as RA 
based on ACR/EULAR 2010 criteria and aged more than 18 years 
old. Routine anamnesis and physical examination were performed 
to review the exclution criteria prior to asking the informed 
consent to participate in this study. The exclusion criteria include 
pregnancy, having other autoimmune disease besides RA, 
suffering from acute severe infection or acute car-diovascular 
event such as coronary heart disease, heart failure, or stroke, 
having neoplasm or chronic inflammatory disease such as 
tuberculosis, smoking or history of smoking within the last five 
years, dyslipidemia, hypertension, diabetes mellitus, and refusing 
to participate in this study.  
Subjects fulfilling the study criteria underwent further an-
amnesis and physical examination regarding age, sex, disease 
duration, and ongoing therapy. Data might be obtained ret-
rospectively in the medical record as well. Laboratory tests of 
inflammatory marker ESR and CRP were performed in ac-
cordance to the routine procedure in Cipto Mangunkusumo 
National General Hospital. The tests for IL-6 and sE-selectin 
were performed using 5 mL venous blood sample, which was 
sentrifuged for 15 minutes with the speed of 3,000 rpm. The 
tests were carried out on the serum using enzyme-linked im-
munosorbent assay (ELISA).  
Each variable was presented descriptively and analyzed 
bivariately using SPSS 20.0. Pearson correlation test was per-
formed if the data was normally distributed, whereas Spear-




Of 40 subjects participating in this study, 39 subjects (97.5%) 
were female with the mean age of 44.9 years, the median dis-
ease duration of 36 months, and receiving DMARD either as 
monotherapy or in combination. Based on DAS28 CRP, most 
subjects were grouped into low (32.5%) and moderate (27.5%) 
category. The other demographic profiles were de-scribed in 
Table 1. 
 
Table 1. Characterstics of the Study Subjects 
 
Characteristics Value (n=40) 
Sex, n (%)  
Male 1 (2.5) 
Female 39 (97.5) 
Age (years), mean (SD) 44.9 (13.1) 
Disease duration (months), median (min-max) 36 (2-300) 
ESR (mm), median (min-max) 43.5 (10-130) 
CRP (mg/L), median (min-max) 5.15 (0,3-105.2) 
DAS28 CRP, median (min-max) 3.13 (1,32-7.68) 
Remision (%) 25 
Low (%) 32.5 
Moderate (%) 27.5 
High (%) 15 
Therapy  
Methotrexate (%) 20 
Methotrexate + Steroid (%) 72.5 
Sulfasalazine +Steroid (%) 2.5 
IL-6 (pg/mL), median (min-max) 2.3 (1.04-279.09) 
sE-selectin (ng/mL), median (min-max) 31.66 (15.26-87.8) 
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IL-6 and sE-selectin level in this study were described in 
table 1. This study did not compare the level of those inflam-
matory mediator and adhesion molecule to the normal control. 
Spearman correlation test between serum IL-6 and sE-selectin 
showed weak positive correlation which was not statistically 
significant (r=0.232; p=0.149; Figure 1). 
 
Figure 1. Scatterplot showing the correlation between serum 




















r = 0.232  







Rheumatoid arthritis is an inflammatory disease affecting the 
joints (arthritis), has a chronic nature, and is generally preva-
lent on young-aged female. This study recruited subjects with 
similar characteristics; most of the subjects were female 
(97.5%) with the mean age of 44.9 + 13.1 years. These char-
acteristics corresponded as well with the systematic review by 
Cross, et al. that female contributed twice the prevalence of 
RA compared to male (0,35% vs 0,15%)13 and the meta analy-
sis by Rudan, et al. that female contributes five times more 
than male to the prevalence of RA.14  
Assessing the relationship between inflammation and ath-
erosclerosis in RA, this study was the first study in Indonesia 
observing the relationship between inflammatory mediator IL-6 
and biomarker of endothelial dysfunction E-selectin. This study 
found a weak positive correlation that was not statisti-cally 
significant between those variables (r=0.232; p=0.149). This 
finding was different to the report by Dessein, et al. in 2005 
(r=0.359, p<0.006)11 and 2013 (r=0.392, p<0.0001),15 but similar 
to the report by Foster, et al. (r=0.200, p=0.155).16  
Interleukin-6 is one of the inflammatory mediators which is 
known to contribute in the pathogenesis of RA. This cyto-kine 
induced acute phase reactant such as CRP and played a role in 
endothelial activation as well as increased the syn-thesis of 
cholesterol and reduced the secretion of cholesterol; thereby it 
was atherogenic. This cytokine was thought to be the 
nontraditional cardiovascular risk factor resulting in the increase 
of cardiovascular event by triggering atherosclerosis. 
Atherosclerosis was initially started with endothelial dysfunc-
tion showed by increased expression of endothelial adhesion 
molecule such as E-selectin.5,6,8-10 Unfortunately, this study, as 
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well as other studies, had still not found a consistent relation-ship 
between those two variables. The difference among this study 
compared to the other studies could be explained by the difference 
in study subject characterstics and the influence of traditional 
cardiovascular risk factors as well as the difference in the disease 
severity and the received therapy.  
The subjects in this study had younger age (44.9 + 13.1 
years) compared to the ones described by Dessein, et al. (57 
(27-81) years in 200511 and 55.8 + 10.2 years in 201315) and 
Foster, dkk. (58.5 + 14 years).16 Various studies had reported 
that aging was independently contributed to atherogenesis 
process by elevating oxidative stress and the level of inflam-
matory mediators. Higher level of IL-6 reported by Dessein, 
et al. (5.4 (0.5-186.3) pg/ml)15 compared to the one in this 
study (2.3 (1.04-278.09) pg/mL) could be explained by the 
difference in age, which became a factor in causing the dif-
ference among those studies. Therefore, age difference might 
be a confounding factor in the relationship between IL-6 and 
E-selectin.  
Unlike both studies by Dessein, et al., this study excluded 
subjects with traditional cardiovascular risk factors, includ-ing 
hypertension, diabetes mellitus, metabolic syndrome, and 
hypercholesterolemia. Those factors were well-known to play 
some role in the process of endothelial dysfuntion as well as in 
the increase of either inflammatory mediators or biomarkers of 
endothelial dysfunction. Those differences might also have a 
potential in causing the discrepancy of result with this study.  
In terms of disease severity, this study had subjects with 
lower DAS28 CRP value (3.13 (1.32-7.68)) compared with the 
ones reported in both studies by Dessein, et al. (4.2 + 1.3).11,15 
This reflected higher inflammation process in the study by 
Dessein, et al., which might result in higher potential of 
endothelial dysfunction event in those studies.  
The last factor suspected to cause differences between this 
study and the study conducted by Dessein, et al. was the dif-
ference in therapy received by the subjects. It was found that 
the use of steroid in this study was much higher than the one 
found in the report by Dessein, et al. (75% vs 15%).15 Some 
studies had reported that steroid inhibited the “shedding” pro-
cess by posttranslational modification of adhesion molecules 
that resulted in reduced expression of E-selectin. In vitro study 
by Cronstein, et al.17 showed that dexamethasone inhibited the 
mRNA of E-selectin in human umbilical vein endothelial cells 
(HUVECs) stimulated with LPS and IL-1. A study by Ray, et 
al.18 had also reported that glucocorticoid inhibited the promo-
tor of NF-KB, which would result in reduced expression of E-
selectin.  
While the study by Foster, et al. had similar age character-
istics compared to the ones by Dessein, et al. and included tra-
ditional cardiovascular risk factors in his study as well, Foster, 
et al. reported different result. This difference was thought due 
to the difference in therapy between those studies. Unfortu-
nately, Foster, et al did not include the variable of therapy in 
the demographic characteristics.16  
Measuring the power of this study according to computer-ized 
calculation using application by computing the data of correlation 
coefficient, α value, and sample size, the power for correlation 
coefficient between IL-6 and sE-Selectin in this 
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study was 30%. This number was considered low comparing 
to the target power set in the early sample size calculation, 
which was 80%. Therefore, the correlation coefficient in this 
study was still deemed unable to explain the exact correlation 
between those variables. The difference between this study 
and the report by Dessein, et al.,11 which showed a significant 
result, was due to differences in subject characteristics. Des-
sein, et al. included traditional cardiovascular risk factors in 
the study. Therefore, sample size calculation referring to the 
correlation coefficient from the study by Dessein, et al. was 
not applicable to this study, which resulted in more sample 
size needed in this study. 
 
Conclusions 
There was weak positive correlation between IL-6 and E-se-lectin 
in RA. However, the result was not statistically signifi-cant. This 
finding was thought to occur due to the younger age of recruited 
subject with shorter duration of disease, the exclu-sion of 
traditional cardiovascular risk factors, the difference in the 
severity of disease, and the variation of therapy received. 
 
Suggestions 
This is the first study in Indonesia evaluating the correlation 
between IL-6 as inflammatory mediator and E-selectin as a 
biomarker of endothelial dysfunction in RA. Further studies, 
including a similar study with larger sample size or without 
re-striction of traditional cardiovascular risk factors, were 
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